Today: 20 May 2026
Browse Category

ASX:PME 24 November 2025 - 6 March 2026

Why Pro Medicus (ASX:PME) shares jumped 4.6% today

Why Pro Medicus (ASX:PME) shares jumped 4.6% today

Pro Medicus shares jumped 4.6% to A$121.49 on Thursday, valuing the company at about A$12.1 billion. The stock remains down 53% over the past year despite recent gains. Interim results showed revenue up 28.4% to A$124.8 million, with profit boosted by a large fair value gain on a 4D Medical investment. An on-market buyback is underway through March 2026.
5 March 2026
··
ASX 200 today: Australia shares seen softer after tariff uncertainty jars banks, tech

ASX 200 today: Australia shares seen softer after tariff uncertainty jars banks, tech

ASX 200 futures traded around 8,988 early Tuesday, about 0.4% below Monday’s close after the index fell 0.61% on U.S. tariff uncertainty. Growth stocks and banks dropped, while resources and gold miners outperformed. The Australian dollar slipped 0.2% to 70.68 U.S. cents. Traders await January inflation data due Wednesday.
23 February 2026
········
ASX 200 Today: Index Rebounds From Near Six‑Month Low as Banks, Miners Lift the Market – 24 November 2025

ASX 200 Today: Index Rebounds From Near Six‑Month Low as Banks, Miners Lift the Market – 24 November 2025

The S&P/ASX 200 rose about 1.1% to 8,507 by late morning Monday, rebounding after a 1.6% drop Friday that erased nearly $40 billion in value. All major sectors traded higher, led by financials and industrials. The index remains roughly 7–8% below its October record high, following four straight weekly losses. Investors await a key inflation report due Wednesday.
24 November 2025
·····

Stock Market Today

  • Celestica Inc: Over 20% Annualized Returns Anticipated Amid AI Hardware Surge
    May 19, 2026, 6:14 PM EDT. Celestica Inc (CLS) stands to gain from the growing demand for artificial intelligence (AI) hardware. This anticipated trend is expected to boost both the company's revenue (top-line) and profit margins, suggesting strong financial performance ahead. Analysts rate CLS stock as a Strong Buy, highlighting potential annualized returns exceeding 20%. Investors eyeing tech manufacturing and AI sectors may find Celestica's outlook particularly compelling amid evolving market dynamics.

Latest articles

Exxon, Chevron Warn Oil Shock Isn’t Over As Hormuz Squeeze Drains Reserves

Exxon, Chevron Warn Oil Shock Isn’t Over As Hormuz Squeeze Drains Reserves

20 May 2026
HOUSTON, May 19, 2026, 17:07 CDT Exxon Mobil and Chevron are warning that oil markets have not fully priced the shock from the effective closure of the Strait of Hormuz, as new reserve and inventory data show governments are burning through buffers to keep fuel moving. The warning matters now because the cushion is shrinking. The U.S. government shipped a record 9.9 million barrels out of the Strategic Petroleum Reserve last week, while the International Energy Agency said commercial inventories were being depleted rapidly, with only “several weeks” left in some buffers. (Reuters) Oil prices eased Tuesday after U.S. Vice
Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

20 May 2026
Toll Brothers shares rose 2.7% to $127.50 in after-hours trading after quarterly profit and revenue topped Wall Street forecasts. Fiscal Q2 net income fell to $260.6 million from $352.4 million a year earlier, while home sales revenue dropped to $2.51 billion. The company raised its full-year delivery and pricing guidance despite high mortgage rates and softer industry sentiment.
POET Raises $400 Million, Shares Don’t Catch a Bid

POET Raises $400 Million, Shares Don’t Catch a Bid

20 May 2026
POET Technologies shares fell 8.02% to $13.07 on Tuesday, despite closing a $400 million financing deal with MMCAP International. The company issued over 19 million shares and warrants at $21 per package, aiming to expand production capacity tenfold. POET reported a first-quarter net loss of $12.3 million on $503,389 in revenue. A new $50 million order from Lumilens could scale to $500 million over five years.
Go toTop